Eton Pharmaceuticals shares hit record high after Hemangeol relaunch
Updated
Updated · MarketWatch · May 1
Eton Pharmaceuticals shares hit record high after Hemangeol relaunch
9 articles · Updated · MarketWatch · May 1
The stock rose 18% to $28.48 after touching $29.80 intraday, extending its gain this year to 68%.
Eton said the FDA-approved oral solution is now available exclusively through Anovo Specialty Pharmacy and is being launched with its Eton Cares patient support service.
Hemangeol treats infantile hemangiomas, non-cancerous tumours that typically appear in the first days or weeks of a baby's life.
Is Eton’s exclusive pharmacy deal a new blueprint for rare disease drugs, or a risky bet for patients?
A vital infant drug is now sold exclusively. Does this new model help families or just boost corporate profits?